Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial

Lillie D.Shockney, RN, BS, MAS, HON- ONN-CG
The Treatment Experience

DonFeiler
Brand Engagement

IraHaimowitz
Closed-Loop Marketing

EdCohen, PharmD, FAPhA
Pharmacy’s Significance

AaronDavis
Value & Access

JuliaLaurin
Medication Adherence

BudBilanich
Success Coach

BrendaSnow
Authentic Patient Voice

AdrienneStevens, EdD, MBA
HCP Insights

DavidLinetsky
Point-of-Care Marketing

ErinDeRuggiero
Non-Personal Promotion

SarahCaldwell
Data & Analytics